UNSPSC 51161710: Calfactant

This classification denotes a respiratory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q4K217VGA9. European Medicines Agency schedules Calfactant in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13207MIG. As of Q4 2014, CALFACTANT remains the US FDA Preferred Term for this commodity.

UNSPSC 51161710 Calfactant is a Commodity code that does not align with the state and local procurement activity currently tagged under it. The recent opportunities posted under this code involve naloxone procurement, on-site pharmacy services, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products — none of which address surfactant replacement therapy or neonatal respiratory distress treatment, which calfactant is designed to deliver. The mismatch between the code's nominal scope and the actual work being solicited suggests either a classification error in the sourcing system or that state and local agencies are using this code as a catch-all for broader pharmaceutical and pharmacy service procurement. The issuing bodies include county health departments (Seminole County, Florida), county government health plans (Hall County, Georgia), state health and human services agencies (Texas HHS Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across Oregon and other jurisdictions).

Activity clusters in Florida, Georgia, Texas, and Minnesota, with the Minnesota cooperative purchasing vehicle serving the broadest geographic footprint. Representative recent solicitations include Seminole County's IFB60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023); Hall County's RFQ/P #47-010 for on-site pharmacy services at a government family health center serving 3,005 eligible individuals (due June 4, 2026); Texas HHS Commission's RFI HHS0017013 exploring direct-to-manufacturer prescription fulfillment models (posted April 3, 2026); and MMCAP's S1070000015802 for generic multi-source pharmaceuticals and OTC products across state and local facilities (due March 26, 2026). Given the absence of calfactant-specific activity in the recent opportunities block, this code shows little relevant current procurement momentum.